



Supplementary Figure 1. Proportion of patients achieving ASDAS <2.1 and BASDAI50 responses for 116 weeks of continuous IXE treatment for (A, C) biologic DMARD-naïve patients and (B, D) TNFi-experienced patients. Missing data among the Continuously treated with IXE patients was imputed using NRI. The study was not designed to allow comparison between bDMARD-naïve patients with r-axSpA and bDMARD-naïve patients with nr-axSpA. Data are presented as the proportion (%) of patients, both NRI (black) and observed (grey) values. ASDAS, Ankylosing Spondylitis Disease Activity Score; axSpA, axial spondyloarthritis; BASDAI50, 50% improvement in Bath Ankylosing Spondylitis Disease Activity Index; nr-axSpA, non-radiographic axSpA; r-axSpA, radiographic axSpA; TNFi, tumour necrosis factor inhibitor.